Brolucizumab Injection (Beovu) 27.6mg/0.23ml – Factory low price wholesale

Brolucizumab Injection (Beovu) 27.6mg/0.23ml – Factory low price wholesale

(1 条用户评价)

$2.00

Beovu (Brolucizumab Injection) is supplied in a 0.23ml single-dose vial containing 27.6mg of active ingredient. Manufactured by Alcon-Couvreur N.V. and NMPA-approved under SJ20250019. Intended for non-clinical research use only.?For wholesale prices, other specifications and uses, please consult our staff?

EMI starting from $0.00/month - View Plans
Compare
分类:

描述

Brolucizumab is a humanized single-chain antibody fragment (scFv) targeting vascular endothelial growth factor A (VEGF-A). It is used in ophthalmological research to study mechanisms of wet age-related macular degeneration (wet AMD) and retinal vascular permeability.

Beovu delivers high molar concentration of anti-VEGF activity in a compact 27.6mg/0.23ml dosage form, enabling researchers to model retinal neovascularization, angiogenesis inhibition, and anti-VEGF pathways in both in vitro and in vivo settings.

?? This product is strictly intended for laboratory research use and is not approved for human or veterinary administration.


Product Specifications

Parameter Details
Product Name Brolucizumab Injection (Beovu)
Generic Name Brolucizumab
CAS Number 1612181-62-6
Molecular Formula Not applicable (monoclonal antibody fragment)
Molecular Weight ~26 kDa
Dosage Form Injection (lyophilized or liquid vial)
Strength 27.6mg in 0.23ml
Quantity 1 vial per box
Approval Number SJ20250019 (China NMPA)
Product Code 86978679002796
Barcode 86978679002796
Manufacturer Alcon-Couvreur N.V. (Belgium)
Intended Use For laboratory research only
Storage Store refrigerated at 2–8°C; do not freeze or shake

Mechanism & Research Applications

Brolucizumab binds VEGF-A with high affinity, preventing interaction with VEGF receptors on endothelial cells, thereby suppressing angiogenesis and vascular leakage. It enables researchers to investigate:

  • Pathogenesis and treatment of wet age-related macular degeneration (wet AMD)

  • Experimental retinal angiogenesis models

  • Comparative efficacy of anti-VEGF agents

  • VEGF pathway inhibition and downstream signaling

  • Ocular pharmacokinetics of antibody fragments


Observed Effects in Research Models

In preclinical studies, Brolucizumab has shown:

  • Potent inhibition of neovascularization

  • Reduction in retinal thickness and fluid accumulation

  • Minimal systemic exposure due to small molecular size

  • Transient inflammation in animal eye models (dose-dependent)

Appropriate research protocols and animal care guidelines should be followed.


Safety & Handling

  • Use Restriction: Laboratory research use only.

  • Personal Protective Equipment: Gloves, goggles, lab coat

  • Storage: Refrigerate (2–8°C); avoid freezing

  • Disposal: Dispose of biological waste per local biosafety guidelines


Research Use Disclaimer

This product is strictly intended for laboratory research use only. It is not for clinical, therapeutic, diagnostic, or veterinary use. Misuse may result in legal or health risks. Always follow institutional biosafety and handling protocols.

其他信息

重量 1 公斤
尺寸 26 × 23 × 26 厘米

Brolucizumab Injection (Beovu) 27.6mg/0.23ml – Factory low price wholesale 有 1 个评价

  1. slw

    Thanks

添加评价

您的邮箱地址不会被公开。 必填项已用 * 标注

Q1: Is Beovu Injection suitable for clinical or therapeutic use?

No, this product is for experimental use only. It is not approved for diagnostic, clinical, or therapeutic purposes.

Q2: Can I order this product in bulk quantities?

Yes, we support both wholesale and retail distribution. Please contact us for bulk pricing and logistics.

Q3: Do you provide COA and SDS documentation?

Yes, both the Certificate of Analysis (COA) and Safety Data Sheet (SDS) are available upon request for institutional buyers.

Q4: What research models commonly use Brolucizumab Injection?

It is frequently used in wet AMD animal models, anti-VEGF comparative research, and in vitro angiogenesis inhibition studies.

Q5: What makes Brolucizumab Injection (Beovu) unique among anti-VEGF agents?

Unlike larger monoclonal antibodies, Brolucizumab’s single-chain structure allows for higher molar dosing and deeper retinal penetration, making it ideal for VEGF-inhibition research and wet AMD studies.


EMI Options

Select at least 2 products
to compare